首页> 外文期刊>Advances in Breast Cancer Research >&i&In-Silico&/i& Identification of Anticancer Compounds; Ligand-Based Pharmacophore Approach against EGFR Involved in Breast Cancer
【24h】

&i&In-Silico&/i& Identification of Anticancer Compounds; Ligand-Based Pharmacophore Approach against EGFR Involved in Breast Cancer

机译:& i& in-silico& / i& 鉴定抗癌化合物; 基于Ligand的药物疗法接种egFR参与乳腺癌

获取原文
           

摘要

Objective: Breast cancer is a public health challenge on a global scale that is caused by environmental or genetic factors. Breast cancer is affecting both males and females, but there is still a lack of effective drugs with improved potency and admissibility against breast cancer as many of the breast cancer drugs have severe side effects. Methods: The docking approach has been used to find a new compound for breast cancer with more efficacy and tolerance and with lesser side effects. A ligand-based pharmacophore approach has been generated for 39 anticancer compounds with significance for the development of new drugs. Result: Through docking, the approach found new lead compoun ds for breast cancer. The proposed pharmacophore model in this study contains two HBAs and one HYD , one hydrophobic domain and two Aromatic rings and the estimated distance range is minimum to maxi mum of derived pharmacophore features. Conclusion: Based on this research, it is proposed that these two lead compounds may be able to be used against EGFR in breast cancer. New compounds can be identified based on common features in the Pharmacophore model. 3D pharmacophore triangle could be used for further studies because this pharmacophore has better merging and in the future for more studies can suggest the same distance range of pha rmacophore features as this pharmacophore.
机译:目的:乳腺癌是一种对环境或遗传因素引起的全球规模的公共卫生挑战。乳腺癌正在影响雄性和女性,但仍然缺乏有效的药物具有改善的效力和免受乳腺癌可否受理,因为许多乳腺癌药物具有严重的副作用。 方法:对接方法已被用于寻找乳腺癌的新化合物,具有更多功效和耐受性,副作用较小。为39种抗癌化合物产生了一种具有重要性的一种具有重要性的基于配体的药物化学方法,这对于新药的开发具有重要意义。 结果:通过对接,该方法发现了新的铅癌铅癌DS。本研究中所提出的药疗法模型含有两个HBA和一个HYD,一个疏水结构域和两个芳环,并且估计的距离范围最小为Maxi Mum的衍生药长特征。 结论:基于该研究,提出这两种铅化合物可以用于乳腺癌中的EGFR。可以基于药效线模型中的共同特征来鉴定新化合物。 3D Pharmacore三角形可用于进一步研究,因为这种药镜更好地合并,未来对于更多研究可以提出与此药质色团的相同距离范围的PHA Rmacophore特征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号